VRTX

Vertex Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality8/10
  • Growth↓ 4/10
  • Value↓ 2/10
Vertex Pharmaceuticals sales and earnings growth
VRTX Growth
Neutral
  • Revenue Y/Y↑ 8.90%
  • EPS Y/Y↑ 843.27%
  • FCF Y/Y↑ 504.13%
Vertex Pharmaceuticals gross and profit margin trends
VRTX Profitability
Great
  • Gross margin ↑ 86.20%
  • EPS margin↑ 32.90%
  • ROIC 5Y↑ 41.37%
Vertex Pharmaceuticals net debt vs free cash flow
VRTX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 350.1

Vertex Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗